Follow-up characteristics of participants grouped by status of IAPD from 2015 to 2020
| Follow-up characteristics | Persistent no IAPD | Incident IAPD | Persistent IAPD | Remittent IAPD |
| IAP level (U/g stool) (for defining IAPD) | Baseline: ≥65.0 Follow-up: ≥65.0 | Baseline: ≥65.0 Follow-up:<65.0 | Baseline: <65.0 Follow-up: <65.0 | Baseline: <65.0 Follow-up: ≥65.0 |
| Number of participants (N=574) | 125 (male 31; female 94) | 63 (male 16; female 47) | 266 (male 80; female 186) | 120 (male 41; female 79) |
| Age group (years) at baseline | 30–60 | 30–60 | 30–60 | 30–60 |
| Average age (years) at baseline | 40.2±8.9 | 42.1±10.1 | 43.2±8.8* | 39.8±9.1 |
| Height (m) at baseline | 1.5±0.1 | 1.5±0.2 | 1.5±0.2 | 1.5±0.2 |
| Weight (kg) | 60.3±10.8 | 57.5±9.3 | 59.2±8.8 | 61.4±11.0 |
| BMI (kg/m2) | 26.0±5.3 | 25.6±4.7 | 25.3±3.8 | 25.8±4.4 |
| Systolic BP (mm Hg) | 128.9±17.1 | 133.3±20.4 | 131.6±16.0 | 127.5±16.5 |
| Diastolic BP (mm Hg) | 79.1±9.2 | 81.2±10.2 | 79.8±8.4 | 79.7±8.9 |
| Creatinine (mg/dL) | 0.89±0.21 | 0.97±0.41 | 0.92±0.22 | 0.89±0.29 |
| Cholesterol (mg/dL) | 178.0±32.7 | 189.5±39.0 | 178.2±31.9 | 181.5±36.9 |
| HDL (mg/dL) | 42.4±7.7 | 43.5±9.7 | 42.1±8.8 | 43.3±8.6 |
| LDL (mg/dL) | 103.9±27.3 | 112.5±31.8 | 102.9±26.4 | 106.5±32.1 |
| Triglycerides (mg/dL) | 160.9±68.2 | 166.2±64.1 | 164.5±67.7 | 155.7±63.4 |
| ALT (U/L) | 38.3±16.4 | 33.3±21.7 | 38.4±18.5 | 34.7±16.3 |
| FPG (mmol/L) | 5.6±1.4 | 6.7±3.4* | 6.1±1.7* | 5.8±1.7 |
Data are summarized as mean (average)±SD for each variable.
Statistical significance of the difference between two respective groups was examined using unpaired two-tailed Student’s t-test (reference group: persistent no IAPD).
*p<0.01.
ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoproteins; IAP, intestinal alkaline phosphatase; IAPD, IAP deficiency; LDL, low-density lipoproteins.